Gossamer Bio Financial Results
Gossamer Bio reported Q3 2026 financial results, highlighting the submission of its first New Drug Application (NDA) to the FDA for seralutinib in PAH. The company also noted a structured private placement that provided $25 million upfront and could unlock an additional $125 million upon FDA acceptance of the NDA. Additionally, the company completed a 1-for-80 reverse stock split in September 2026 to regain Nasdaq compliance.
- Term
- Q3 2026
“Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH. Furthermore, FDA acceptance of the application in 2026 would, subject to other customary closing conditions, unlock up to approximately $125 million in additional committed capital to support our priorities, including preparations for a potential launch. We remain focused on supporting the FDA’s review and preparing for a potential commercial launch of seralutinib in 2027.”
Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer